Top

International Urogynecology Journal

Published in:

01-04-2011 | Original Article

Long-term results of intravesical hyaluronan therapy in bladder pain syndrome/interstitial cystitis

Authors: Paul F. Engelhardt, Nike Morakis, Lukas K. Daha, Britta Esterbauer, Claus R. Riedl

Published in: International Urogynecology Journal | Issue 4/2011

Abstract

Introduction and hypothesis

While the short-term efficacy of intravesical hyaluronan for bladder pain syndrome/interstitial cystitis (BPS/IC) has been demonstrated, no data exist on the long-term outcome of this therapy.

Methods

Seventy BPS/IC patients treated with intravesical hyaluronan therapy from 2001 to 2003 were asked to rate their present status of bladder symptoms on a visual analog scale.

Results

Forty-eight of 70 patients responded after a mean follow-up of 4.9 years. The average initial VAS score of 8.15 had been reduced to 2.71 after therapy and further to 2.14 5 years later. Fifty percent of patients (24/48) reported complete bladder symptom remission at 5 years follow-up without any additional therapy; 41.7% (20/48) with symptom recurrence was improved with hyaluronan maintenance therapy. No improvement was reported by four patients.

Conclusions

Besides a high rate of acute symptom remission, intravesical hyaluronan also shows long-term efficacy in a considerable number of BPS/IC patients.

Toft BR, Nordling J (2006) Recent developments of intravesical therapy of painful bladder syndrome/interstitial cystitis: a review. Curr Opin Urol 16:268–272PubMedCrossRef

Morales A, Emerson L, Nickel JC, Lundie M (1996) Intravesical hyaluronic acid in the treatment of refractory interstitial cystitis. J Urol 156:45–48PubMedCrossRef

Fall M, Oberpenning F, Peeker R (2008) Treatment of bladder pain syndrome/interstitial cystitis 2008: can we make evidence-based decisions? Eur Urol 54:65–78PubMedCrossRef

Porru D, Campus G, Tudino D, Valdes E, Vespa A, Scarpa RM, Usai E (1997) Results of treatment of refractory interstitial cystitis with intravesical hyaluronic acid. Urol Int 59:26–29PubMedCrossRef

Bade JJ, Laseur M, Nieuwenburg A, van der Weele LT, Mensink HJ (1997) A placebo controlled study of intravesical pentosanpolysulfate for the treatment of interstitial cystitis. Br J Urol 79:168–171PubMed

Parsons CL, Housley T, Schmidt JD, Lebow D (1994) Treatment of interstitial cystitis with intravesical heparin. Br J Urol 73:504–507PubMedCrossRef

Steinhoff G, Ittah B, Rowan S (2002) The efficacy of chondroitin sulfate 0.2% in treating interstitial cystitis. Can J Urol 9:1454–1458PubMed

Nickel JC, Egerdie B, Downey J, Singh R, Skehan A, Carr L, Irvine-Bird K (2009) A real-life multicentre clinical practice study to evaluate the efficacy and safety of intravesical chondroitin sulphate for the treatment of interstitial cystitis. BJU Int 103(1):56–60PubMedCrossRef

Riedl CR, Engelhardt PF, Daha KL, Morakis N, Pflüger H (2008) Hyaluronan treatment of interstitial cystitis/painful bladder syndrome. Int Urogyneocol J Pelvic Floor Dysfunct 19(5):717–721CrossRef

10.

Kallestrup EB, Steinunn S, Jørgense S, Nordling J, Hald T (2005) Treatment of interstitial cystitis with Cystistat®: a hyaluronic acid product. Scand J Urol Nephrol 39:143–147PubMedCrossRef

11.

Daha LK, Riedl CR, Hohlbrugger G, Knoll M, Engelhardt PF, Pfluger H (2003) Comparative assessment of maximal bladder capacity, 0.9% NaCL versus 0.2M KCl, for the diagnosis of interstitial cystitis: a prospective controlled study. J Urol 170:807–809PubMedCrossRef

12.

Hurst RE (1994) Structure, function, and pathology of proteoglycans and glycosaminoglycans in the urinary tract. World J Urol 12:3–10PubMedCrossRef

13.

Leppilahti M, Hellström P, Tammela TLJ (2002) Effect of diagnostic hydrodistension and four intravesical Hyaluronan Instillations on bladder ICAM-1 intensity and association of ICAM-1 intensity with clinical response in patients with interstitial cystitis. Urology 60:46–51PubMedCrossRef

14.

Schulz A, Vestweber AM, Dressler D (2009) Anti-inflammatory action of a hyaluronic acid-chondroitin sulphate preparation in an in vitro bladder model. Akt Urol 40(2):109–112CrossRef

15.

Parsons CL, Forrest J, CJ CJ, the Elmiron Study Group (2002) Effect of pentosan polysulfate therapy on intravesical potassium sensitivity. Urology 59:329–334PubMedCrossRef

16.

Gupta SK, Pidcock L, Parr NJ (2005) The potassium sensitivity test: a predictor of treatment response in interstitial cystitis. BJU Int 96:1063–1066PubMedCrossRef

17.

Teichman JM, Nielsen-Omeis BJ (1999) Potassium leak test predicts outcome in interstitial cystitis. J Urol 161:1791–1796PubMedCrossRef

18.

Daha L, Riedl CR, Lazar D, Simak R, Pflüger H (2008) Effect of intravesical glycosaminoglycan substitution therapy on bladder pain syndrome/interstitial cystitis, bladder capacity and potassium sensitivity. Scand J Urol 42(4):369–372CrossRef

Title: Long-term results of intravesical hyaluronan therapy in bladder pain syndrome/interstitial cystitis
Authors: Paul F. Engelhardt
Nike Morakis
Lukas K. Daha
Britta Esterbauer
Claus R. Riedl
Publication date: 01-04-2011
Publisher: Springer-Verlag
Published in: International Urogynecology Journal / Issue 4/2011
Print ISSN: 0937-3462
Electronic ISSN: 1433-3023
DOI: https://doi.org/10.1007/s00192-010-1294-y

At a glance: The STEP trials

Springer Medicine

Long-term results of intravesical hyaluronan therapy in bladder pain syndrome/interstitial cystitis

Abstract

Introduction and hypothesis

Methods

Results

Conclusions

At a glance: The STEP trials

Springer Medicine

Abstract

Introduction and hypothesis

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 4/2011

Lead migration after sacral neuromodulation: surgical revision in fascial versus tined anchoring systems

Injury of the corona mortis during vaginal tape insertion (TVT-Secur™ using the U-Approach)

Clinical study of ischia spinous fascia fixation—a new pelvic reconstructive surgery

Laparoscopic sacral colpoperineopexy: abdominal versus abdominal–vaginal posterior graft attachment

Sonographic appearance of transobturator slings: implications for function and dysfunction

Minimum 6-year outcomes for interstitial cystitis treated with sacral neuromodulation